← All trials
NCT06156566
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Dec 5, 2023
- Last posted
- Dec 5, 2023
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Utrecht UniversityLead sponsor
- Erasmus University RotterdamCollaborator
- Utrecht UniversitySponsor investigator
- University of AntwerpCollaborator
- Government of FranceCollaborator
- Autonomous University of MadridCollaborator
- Utrecht UniversityOfficial
- European Clinical Research Alliance for Infectious Diseases (ECRAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.